NASDAQ · LMAT
Healthcare · Medical - Instruments & Supplies
$79.47
Down-$0.91 (-1.13%)
Updated Sep 18, 2026, 4:57 AM
SID Score
4.1/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
LMAT closed at $79.47 after 20 trading sessions, down 3.46% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 17, 2026 | $81.07 | $81.08 | $79.37 | $79.47 | 204.84K |
| Sep 16, 2026 | $79.53 | $80.84 | $79.48 | $80.38 | 256.91K |
| Sep 15, 2026 | $80.64 | $80.85 | $79.36 | $80.24 | 303.22K |
| Sep 14, 2026 | $81.39 | $81.82 | $80.00 | $80.77 | 247.91K |
| Sep 11, 2026 | $79.52 | $80.83 | $78.65 | $80.59 | 278.95K |
| Sep 10, 2026 | $78.91 | $80.25 | $78.29 | $78.80 | 291.13K |
| Sep 9, 2026 | $79.11 | $79.80 | $78.34 | $79.47 | 309.09K |
| Sep 8, 2026 | $79.93 | $80.375 | $79.07 | $79.59 | 222.28K |
| Sep 4, 2026 | $79.22 | $81.00 | $79.04 | $80.67 | 167.36K |
| Sep 3, 2026 | $82.57 | $83.07 | $80.00 | $80.49 | 299.11K |
| Sep 2, 2026 | $81.55 | $82.95 | $80.97 | $81.72 | 248.18K |
| Sep 1, 2026 | $80.39 | $81.85 | $79.585 | $81.08 | 346.54K |
| Aug 31, 2026 | $79.58 | $80.95 | $79.05 | $80.28 | 282.76K |
| Aug 28, 2026 | $80.17 | $80.97 | $79.15 | $80.45 | 217.81K |
| Aug 27, 2026 | $79.61 | $79.8752 | $79.0602 | $79.665 | 208.76K |
| Aug 26, 2026 | $78.91 | $79.81 | $78.27 | $79.61 | 150.42K |
| Aug 25, 2026 | $80.24 | $80.77 | $78.285 | $78.97 | 447.67K |
| Aug 24, 2026 | $81.94 | $82.74 | $79.65 | $79.96 | 562K |
| Aug 21, 2026 | $82.37 | $82.875 | $81.6075 | $81.86 | 419.89K |
| Aug 20, 2026 | $83.07 | $83.545 | $81.98 | $82.32 | 269.46K |
The latest Smart Investors Daily articles mentioning LMAT.
LMAT research
Company profile and research snapshot.
LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes towards the proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches and vessel closure systems.It has a single operating segment engaged in the development, manufacturing, and marketing of medical devices and implants, as well as the processing and cryopreservation of human tissues for implantation in patients.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 5, 2026 | Wells Fargo | Equal-Weight | — |
| Jun 3, 2026 | Barrington Research | Outperform | — |
| May 6, 2026 | Citizens | Market Outperform | — |
| May 6, 2026 | Barrington Research | Outperform | — |
| May 6, 2026 | Wells Fargo | Equal-Weight | — |
No generated briefing is available yet.
Benzinga · Sep 8, 2026
L3Harris Technologies (NYSE: LHX) has received an undefinitized contract award from Lockheed Martin, valued at $4.7 billion over seven years, to produce propulsion systems for the PAC-3® Missile Segment Enhancement
Yahoo · Sep 1, 2026
Riverwater Partners, an investment management company, released its ‘Small Cap Strategy’ Q2 2026 investor letter. The letter can be downloaded here. The Small Cap Strategy underperformed the Russell 2000 in the second quarter as the benchmark experienced one of its strongest risk-on rallies in recent memory, although the strategy remained ahead year-to-date. The quarter was defined […]
Yahoo · Aug 27, 2026
BURLINGTON, Mass., Aug. 27, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will participate in three upcoming investor conferences. Wells Fargo 21st Annual Healthcare Conference Tuesday, September 8, 2026, in BostonDorian LeBlanc, CFO, will participate in a Fireside Chat at 8:45 AM ET Morgan Stanley 24th Annual Global Healthcare Conference Wednesday, September 16, 2026, in New York CityDorian LeBlanc, CFO, will participate in a Fireside Chat at 12:
SeekingAlpha · Aug 13, 2026
LeMaitre Vascular stock remains a Buy after a 31% pullback. Click to see LMAT's Q2 drivers, Artegraft growth, margin upside, and valuation reset.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning LMAT.
